



Press Release

Bioceros appoints Mark Treherne as chairman of the Supervisory Board

Utrecht, The Netherlands, August 3rd, 2009.

Dutch biotechnology company Bioceros B.V. today announced the appointment of Dr J. Mark Treherne to join and chair its Supervisory Board.

Mark Treherne (1961), PhD, obtained his PhD in receptor neuropharmacology from Cambridge University (UK) with funding from Merck, before holding a faculty position at the Biozentrum in Basel (Switzerland). Mark now has over 20 years experience in the discovery of novel therapeutic treatments and was formerly at Pfizer in the UK, where he was responsible for research into neurodegenerative diseases. On leaving Pfizer in 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which was sold to BioFocus (now a part of Galapagos (Belgium)). Mark is also Chairman of NeuroDiscovery Ltd (Australia) and Cyclofluidic Limited (UK) and a director of Senexis Limited (UK), Population Genetics Technologies Limited (UK) and Domain Therapeutics S.A. (France).

Commenting on his appointment to the Board, **Dr Treherne** added 'Bioceros is now entering an exciting and important phase of its evolution and I am delighted to be able to work with the Board and its experienced management team. With the strength of its underlying technology platform, I am confident that Bioceros will continue to make significant progress with the growth of its established high-quality service offering, while developing new products to meet new market opportunities'.

Dr Mark de Boer, the leaving chairman of the Board explains: 'We are very pleased that Mark is joining our Supervisory Board. Mark Treherne's broad experience in Biotech, both with service providers and product oriented companies, will be of high value in the further growth of Bioceros'. Dr de Boer will remain member of the Supervisory Board.

About Bioceros B.V.

Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros' technology platform covers early pre-clinical development of monoclonal antibodies, including generation of monoclonal antibodies in mice, making high protein producing mammalian cell lines, assay development and pre-clinical manufacturing at 20L scale in disposable bioreactors. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is preferred vendor of DSM Biologics and Crucell for PER.C6[®] cell line generation services.

Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.

Bioceros is located in Utrecht, the Netherlands. For more information, please visit www.bioceros.com or contact:

Remco M. Brandt, M.Sc. (COO)

Yalelaan 46

3584 CM Utrecht

The Netherlands

Tel. +31 30 253 7910

r.brandt@bioceros.com